Topline results of Phase 2 Long Covid trial do not show evidence of superior efficacy of BC 007 over placebo arm

Berlin Cures AG informs about the status of topline results of BC 007 in Long Covid from the randomized and double-blind Phase 2 trial, which has been conducted by its affiliate Berlin Cures GmbH.

The analyses of the main endpoints did not show evidence of superior efficacy of the BC 007 treatment arms over the placebo arm. The data do suggest, along with previous trials, that BC 007 is safe and well tolerated. Further in-depth analyses have not been conducted. Due to financial constraints, Berlin Cures GmbH was forced to stop all activities. Berlin Cures would like to thank all the patients who participated in the trial, the physicians and clinical trial sites and its supporters who have made it possible to conduct the clinical Phase 2 trial.

Leave a Comment